Intrathecal Compounding Specialist, LLC is recalling several compounded sterile drug preparations, including Fentanyl Citrate, Hydromorphone, Morphine Sulfate PF, and Sufentanil Citrate. The recall affects all units dispensed between October 16, 2017, and November 17, 2017, due to a lack of sterility assurance. Without guaranteed sterility, these injectable medications could contain microorganisms that lead to serious infections. Consumers should contact their healthcare provider or pharmacist immediately if they received these medications from the Scott, Louisiana facility during the specified period.
A lack of sterility assurance in medications injected into the spinal canal (intrathecal) poses a significant risk of life-threatening infections, such as meningitis. While no specific injuries were mentioned in the recall notice, the potential for systemic harm is high whenever the sterile barrier of a compounded drug is compromised.
Healthcare provider consultation and pharmacy refund.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.